Plain-English translation of NCT06833632 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking for special cancer cells in the blood of patients with early-stage lung cancer who are having surgery to remove their tumors. By studying these circulating tumor cells before and after surgery, doctors hope to identify which patients are at higher risk of their cancer coming back, so they can offer those patients better follow-up care or additional treatments.
Even after successful surgery, lung cancer comes back in many patients—sometimes years later. Currently, doctors don't have reliable ways to predict who will have a recurrence early enough to intervene. This study hopes to discover blood-based warning signs that could help doctors catch recurrences sooner or recommend preventive treatments for high-risk patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have blood samples taken before your scheduled lung cancer surgery and at follow-up visits afterward. The research team will analyze these blood samples to look for circulating tumor cells and study what they might tell us about your individual cancer. The study involves about 100 patients total, and your participation helps doctors understand the biology of lung cancer recurrence.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Italy
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment target
~100 participants
Started
May 2023
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Pietro Bertoglio, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.